Non-mulberry silk fibroin nanofibrous dressings functionalized with the antimicrobial peptide LL-37 and growth factors significantly accelerated diabetic wound healing in rabbits, promoting faster tissue formation, blood vessel growth, and organized collagen deposition by 14 days.
Significantly faster healing (P<0.01)Non-mulberry silk dressings with LL-37 peptide healed diabetic wounds faster than all comparison groups at 14 days in a rabbit model
What the researchers found
Non-mulberry silk fibroin (NMSF)-based nanofibrous dressings functionalized with LL-37 antimicrobial peptide and growth factors significantly outperformed mulberry silk (Bombyx mori), PVA, and control dressings for diabetic wound healing (P<0.01 at 14 days).
NMSF dressings demonstrated faster granulation tissue development, angiogenesis (blood vessel formation), and re-epithelialization. Gene expression analysis showed higher matrix metalloproteinase activity and collagen protein expression, indicating enhanced tissue remodeling. At 4 weeks, NMSF-treated wounds showed organized extracellular matrix deposition (collagen types I and III, elastin, reticulin) and higher wound breaking strength compared to all other groups. The non-mulberry silk's inherent RGD cell-binding motifs enhanced cell-material interactions.
Why it matters
Diabetic foot ulcers affect approximately 15-25% of diabetes patients during their lifetime and are a leading cause of non-traumatic limb amputation. Current wound dressings are largely passive. A bioactive dressing that simultaneously delivers antimicrobial peptides (preventing infection) and growth factors (promoting healing) from a natural silk matrix addresses multiple failure points in diabetic wound healing. LL-37 is particularly attractive because it's the only cathelicidin antimicrobial peptide produced by humans, making it intrinsically biocompatible.
How the study worked
Electrospun nanofibrous mats were fabricated from PVA blended with silk fibroin from mulberry (Bombyx mori) and non-mulberry silkworms. Mats were functionalized with growth factors and LL-37 antimicrobial peptide for sustained delivery. Diabetic rabbit models were created using alloxan induction. Wounds were treated for 14 days and followed for 4 weeks. Outcomes included wound closure, histopathology, angiogenesis, re-epithelialization, gene expression (MMPs, collagen), extracellular matrix composition, and wound breaking strength.
What this study cannot tell us
The study used an alloxan-induced diabetic rabbit model, which may not fully replicate the complexity of human diabetic wounds (chronic inflammation, neuropathy, vascular disease). The sample size of rabbits is not specified in the abstract. The 4-week follow-up is relatively short for assessing long-term wound remodeling outcomes. Manufacturing scalability and cost of functionalized silk nanofiber dressings were not addressed. The relative contributions of LL-37, growth factors, and the silk matrix itself to wound healing were not individually quantified.
How to read the evidence
This is a well-designed preclinical animal study with multiple comparison groups and comprehensive outcome measures. The diabetic rabbit model is relevant but does not fully replicate human diabetic wound pathology. No human clinical data.
When this study was published
Published in 2018, this study established the proof-of-concept for LL-37-functionalized silk dressings in diabetic wound healing. The approach continues to be developed and refined in ongoing research.
The bigger picture
This study integrates three advancing fields: antimicrobial peptide therapeutics, silk biomaterials, and advanced wound care. The use of LL-37 — the only human cathelicidin — as both an antimicrobial and wound-healing agent embedded in nanofibers represents a sophisticated peptide delivery approach. As diabetes prevalence continues to rise globally, the need for effective chronic wound treatments grows. Bioactive dressings combining natural biomaterials with therapeutic peptides offer a promising alternative to the standard gauze-and-ointment approach.
Questions still open
- Can the LL-37 release kinetics from silk nanofibers be optimized for longer-duration wound treatment?
- How do these bioactive silk dressings compare to existing advanced wound care products in cost-effectiveness analyses?
- Would human clinical trials of LL-37-functionalized dressings in diabetic foot ulcers replicate the accelerated healing seen in rabbits?
Common questions
What is LL-37 and why is it used in wound dressings?
Why is non-mulberry silk better for wound healing?
Read the original research
Functionalized PVA-silk blended nanofibrous mats promote diabetic wound healing via regulation of extracellular matrix and tissue remodelling.
Journal of tissue engineering and regenerative medicine, 12(3), e1559-e1570
Citation
Chouhan, Dimple; Janani, G; Chakraborty, Bijayashree; Nandi, Samit K; Mandal, Biman B. (2018). Functionalized PVA-silk blended nanofibrous mats promote diabetic wound healing via regulation of extracellular matrix and tissue remodelling.. Journal of tissue engineering and regenerative medicine, 12(3), e1559-e1570. https://doi.org/10.1002/term.2581